

**Table 1—Système International (SI) units for plasma, serum, or blood concentrations**

Measurement	Conventional unit	Conversion factor	SI unit	Significant digits	Suggested minimum increments
Acetoacetate	mg/dl	97.95	μmol/l	XXO	10 μmol/l
Acetone	mg/dl	172.2	μmol/l	XXO	10 μmol/l
Adrenocorticotropin	pg/ml	0.2202	pmol/l	XX	1 pmol/l
Aldosterone	ng/dl	27.74	pmol/l	XXO	10 pmol/l
Amino acids					
Alanine	mg/dl	112.2	μmol/l	XXX	5 μmol/l
α-Aminobutyric acid	mg/dl	96.97	μmol/l	XXX	5 μmol/l
Arginine	mg/dl	57.40	μmol/l	XXX	5 μmol/l
Asparagine	mg/dl	75.69	μmol/l	XXX	5 μmol/l
Aspartic acid	mg/dl	75.13	μmol/l		5 μmol/l
Citrulline	mg/dl	57.08	μmol/l	XXX	5 μmol/l
Cystine	mg/dl	41.61	μmol/l	XXX	5 μmol/l
Glutamic acid	mg/dl	67.97	μmol/l	XXX	5 μmol/l
Glutamine	mg/dl	68.42	μmol/l	XXX	5 μmol/l
Glycine	mg/dl	133.2	μmol/l	XXX	5 μmol/l
Histidine	mg/dl	64.45	μmol/l	XXX	5 μmol/l
Hydroxyproline	mg/dl	76.26	μmol/l	XXX	5 μmol/l
Isoleucine	mg/dl	76.24	μmol/l	XXX	5 μmol/l
Leucine	mg/dl	76.24	μmol/l	XXX	5 μmol/l
Lysine	mg/dl	68.40	μmol/l	XXX	5 μmol/l
Methionine	mg/dl	67.02	μmol/l	XXX	5 μmol/l
Ornithine	mg/dl	75.67	μmol/l	XXX	5 μmol/l
Phenylalanine	mg/dl	60.54	μmol/l	XXX	5 μmol/l
Proline	mg/dl	86.86	μmol/l	XXX	5 μmol/l
Serine	mg/dl	95.16	μmol/l	XXX	5 μmol/l
Taurine	mg/dl	79.91	μmol/l	XXX	5 μmol/l
Threonine	mg/dl	83.95	μmol/l	XXX	5 μmol/l
Tryptophan	mg/dl	48.97	μmol/l	XXX	5 μmol/l
Tyrosine	mg/dl	55.19	μmol/l	XXX	5 μmol/l
Valine	mg/dl	85.36	μmol/l	XXX	5 μmol/l
Amino acid nitrogen	mg/dl	0.7139	mmol/l	X.X	0.1 mmol/l
Amylase	U/l	1.0	U/l	XXO	10 U/l
Androstenedione	μg/l	3.492	nmol/l	XX.X	0.5 nmol/l
Calcitonin	pg/ml	1.0	ng/l	XXO	10 ng/l
Calcium	mg/dl	0.2495	mmol/l	X.XX	0.02 mmol/l
Calcium ion	meq/l	0.500	mmol/l	X.XX	0.01 mmol/l
Carbon dioxide content	meq/l	1.00	mmol/l	XX	1 mmol/l
Cholesterol	mg/dl	0.02586	mmol/l	X.XX	0.05 mmol/l
Citrate (as citric acid)	mg/dl	52.05	μmol/l	XXX	5 μmol/l
Cortisol	μg/dl	27.59	nmol/l	XXO	10 nmol/l
C-peptide	ng/ml	0.331	nmol/l	X.XX	0.01 nmol/l
Creatinine	mg/dl	88.40	μmol/l	XXO	10 μmol/l
Creatinine clearance	ml/min	0.01667	ml/s	X.XX	0.02 ml/s
cyclic AMP	μg/l	3.038	nmol/l	XXX	1 nmol/l
cyclic GMP	μg/l	2.897	nmol/l	XX.X	0.1 nmol/l
Dehydroepiandrosterone	μg/l	3.467	nmol/l	XX.X	0.2 nmol/l
Dehydroepiandrosterone sulfate	ng/ml	0.002714	μmol/l	XX.X	0.1 μmol/l
11-Deoxycortisol	μg/dl	28.86	nmol/l	XXO	10 nmol/l
Epinephrine	pg/ml	5.458	pmol/l	XXO	10 pmol/l
Estradiol	pg/ml	3.671	pmol/l	XXX	1 pmol/l

Downloaded from <http://diabetesjournals.org/care/article-pdf/17/12/1559/15147/17-12-1559.pdf> by guest on 10 October 2024

Table 1—Continued

Measurement	Conventional unit	Conversion factor	SI unit	Significant digits	Suggested minimum increments
Estrone	pg/ml	3.699	pmol/l	XXX	5 pmol/l
Fatty acids, nonesterified	mg/dl	0.01	g/l	X.XX	0.01 g/l
Follicle-stimulating hormone	mIU/ml	1.00	IU/l	XX	1 IU/l
Fructose	mg/dl	0.05551	mmol/l	X.XX	0.1 mmol/l
Galactose	mg/dl	0.05551	mmol/l	X.XX	0.1 mmol/l
Gases					
P <sub>O</sub> <sub>2</sub>	mmHg	0.1333	kPa	XX.X	0.1 kPa
P <sub>CO</sub> <sub>2</sub>	mmHg	0.1333	kPa	X.X	0.1 kPa
Gastrin	pg/ml	1.0	ng/l	XXO	10 ng/l
Gastroinhibitory polypeptide	pg/ml	0.201	pmol/l	XXO	10 pmol/l
Glucagon	pg/ml	1.0	ng/l	XXO	10 ng/l
Glucose	mg/dl	0.05551	mmol/l	XX.X	0.1 mmol/l
Glycerol, free	mg/dl	0.1086	mmol/l	X.XX	0.01 mmol/l
Growth hormone	ng/ml	1.0	μg/l	XX.X	0.5 μg/l
β-Hydroxybutyrate (as β-hydroxybutyric acid)	mg/dl	96.05	μmol/l	XXO	10 μmol/l
17α-Hydroxyprogesterone	μg/l	3.026	nmol/l	XX.X	0.5 nmol/l
Insulin	μU/ml	6.0	pmol/l	XXX	5 pmol/l
Lactate (as lactic acid)	mEq/l	1.0	mmol/l	X.X	0.1 mmol/l
Lipase	U/l	1.0	U/l	XXX	1 U/l
Lipoproteins				X.XX	
LDL (as cholesterol)	mg/dl	0.02586	mmol/l	X.XX	0.05 mmol/l
HDL (as cholesterol)	mg/dl	0.02586	mmol/l	XXX	0.05 mmol/l
Luteinizing hormone	mIU/ml	1.0	IU/l	X.XX	1 IU/l
Norepinephrine	pg/ml	0.005911	nmol/l	XXX	0.01 nmol/l
Osmolality	mOsm/kg	1.0	mmol/kg	XX	1 mmol/kg
Pancreatic polypeptide	pg/ml	0.239	pmol/l	X.XX	1 pmol/l
Phosphate (as inorganic phosphorus)	mg/dl	0.3229	mmol/l	X.XX	0.05 mmol/l
Phospholipid phosphorus	mg/dl	0.3229	mmol/l	XX	0.05 mmol/l
Progesterone	ng/ml	3.180	nmol/l	XX	2 nmol/l
Prolactin	ng/ml	1.0	μg/l	XX	1 μg/l
Protein, total	g/dl	10.0	g/l	XX	1 g/l
Pyruvate (as pyruvic acid)	mg/dl	113.6	μmol/l	XXX	1 μmol/l
Renin	ng · ml <sup>-1</sup> · h <sup>-1</sup>	0.2778	ng · L <sup>-1</sup> · s <sup>-1</sup>	X.XX	0.02 ng · L <sup>-1</sup> · s <sup>-1</sup>
Serotonin	μg/dl	0.05675	μmol/l	X.XX	0.05 μmol/l
Somatostatin	pg/ml	0.611	pmol/l	XX	1 pmol/l
Testosterone	ng/ml	3.467	nmol/l	XX.X	0.5 nmol/l
Thyroid-stimulating hormone	μU/dl	1.0	mU/l	X.X	0.1 mU/l
Thyroxine	μg/dl	12.87	nmol/l	XXX	1 nmol/l
Triiodothyronine	ng/dl	0.01536	nmol/l	X.X	0.1 nmol/l
Urea nitrogen	mg/dl	0.3570	mmol/l	X.X	0.5 mmol/l
Vasoactive intestinal polypeptide	pg/ml	0.331	pmol/l	X.X	1 pmol/l

From Young DS: *Ann Intern Med* 106:114–29, 1987.

## DUALITY OF INTEREST DISCLOSURE FORM FOR AUTHORS OF ARTICLES IN AMERICAN DIABETES ASSOCIATION PUBLICATIONS

I have read the American Diabetes Association's Duality of Interest Policy Statement (found in the January and July issues of *Diabetes* and *Diabetes Care*), and I am indicating below that I have or have not had in the previous 12 months a relevant duality of interest with a company whose products or services are *directly* related to the subject matter of my manuscript. A relevant duality of interest includes employment, membership on the board of directors or any fiduciary relationship, membership on a scientific advisory panel or other standing scientific/medical committee, ownership of stock, receipt of honoraria or consulting fees, or receipt of financial support or grants for research. Company is defined as a for-profit concern engaged in the development, manufacture, or sale of pharmaceutical or biomedical devices or supplies.

**Each author must sign this form.** (The form may be photocopied if needed.)

	<b>Check each area that applies</b>					
	Yes	No	Yes	No	Yes	No
Employment	_____	_____	_____	_____	_____	_____
Membership on an advisory panel, standing committee or board of directors	_____	_____	_____	_____	_____	_____
Stock shareholder	_____	_____	_____	_____	_____	_____
Honoraria or consulting fees	_____	_____	_____	_____	_____	_____
Grant/research support	_____	_____	_____	_____	_____	_____
Author (please type or print)	_____		_____		_____	
Signature	_____		_____		_____	
Date	_____		_____		_____	

For each item checked "yes," please list on a separate sheet of paper the third-party organization with whom you have relevant affiliations or interests. Please provide sufficient information to enable the American Diabetes Association to make an informed decision. Include 1) the nature of the activity that is a relevant duality, 2) the type of financial arrangement, if any, between you and the third party, and 3) a description of the business or purpose of the third party. Please see the following sample disclosures.

### **SAMPLE DISCLOSURES FOR AUTHORS**

#### **Employment**

I am employed by Exacta Pharmaceutical Company (6250 Longwood Avenue, Any City, Missouri). My employer manufactures and markets pharmaceuticals related to the treatment of diabetes and its complications.

#### **Board Membership**

I am on the board of directors of the Exacta Pharmaceutical Company, a manufacturer of pharmaceuticals related to the treatment of diabetes.

#### **Stock Shareholder**

I, or my immediate family, hold stock in the following companies that make products related to the treatment or management of diabetes and its complications:

XYZ Corporation  
LMN Corporation

#### **Honoraria or Consulting Fees**

I have received honoraria for speaking engagements from the following:

XYZ Corporation  
LMN Corporation

I am a paid consultant of the XYZ Corporation.

#### **Grants**

The XYZ Corporation is providing funds to my laboratory in order to conduct studies on a new drug to treat diabetic neuropathy.

By answering "yes" in any category, the Association will disclose the relevant duality of interest. The Association will make the disclosure by placing an asterisk by the author's name, and in a footnote describe the nature of the duality of interest, e.g., stock ownership or grant support, and the third party involved.

**This form must be returned with your submission. Make additional copies as needed for all authors. Failure to complete the disclosure may delay or prevent publication of your article.**

## COPYRIGHT TRANSFER AND STATEMENT OF ORIGINALITY

We approve the submission of this paper to the American Diabetes Association for publication and have taken due care to ensure the integrity of this work. We confirm that neither the manuscript nor any part of it has been published or is under consideration for publication elsewhere (abstracts excluded). Any reference to or use of previously published material protected by copyright is explicitly acknowledged in the manuscript.

If this work was produced by an employee of the United States Government as part of his/her official duties, no copyright exists and therefore cannot be transferred. Any co-authors **not** employed by the federal government must sign the copyright transfer agreement.

If this work was produced for an employer as a "work made for hire," an authorized representative of that employer must sign on the appropriate line below.

The undersigned hereby assign copyright for the manuscript entitled

---

---

to the American Diabetes Association upon its acceptance for publication (attach an additional page for signatures if necessary; **all** authors must sign):

---

(Author)

---

(Author)

---

(Author)

---

(Author)

---

(Author)

---

(Author)

The above title constitutes a "work for hire;" as an authorized agent of the employer, I transfer copyright to the American Diabetes Association (no patent rights are transferred):

---

Agent

---

Title

This work was produced on behalf of the United States Government and therefore no copyright exists.

---

(Author)

---

(Author)

---

(Author)

---

(Author)